poisar

Stocks · News reference

Novo Nordisk Receives FDA Approval for Sogroya® in Children with Turner Syndrome

Fiscal.ai

The US Food and Drug Administration (FDA) has approved Novo Nordisk's once-weekly growth hormone injection, Sogroya® (somapacitan-beco), for children aged 2.5 years and older with growth failure associated with Turner Syndrome.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolProsper Junior Bakiny

    Prediction: This Software-as-a-Service Stock Will Beat the Market Through 2031

    Veeva Systems, a leader in cloud-based solutions for life sciences companies, is positioned to beat the market through 2031. The company's recent AI launches (Vault AI and Veeva Falcon) enhance client workflows, while its $6 billion revenue target by 2030 and strong switching costs suggest continued growth. With current 14.5x price-to-sales ratio, the stock could see 79.5% upside if it maintains valuation multiples while reaching its revenue goal.

  2. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.